Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 57.3%

Pyxis Oncology, Inc. (NASDAQ:PYXS) saw a significant decrease in short interest during the month of December. As of December 15th, there was short interest totaling 1,933,041 shares, a decrease of 57.3% from the November 30th total of 4,523,744 shares. Approximately 3.5% of the shares of the stock are short sold. Based on an average daily volume of 645,262 shares, the short-interest ratio is presently 3.0 days. Based on an average daily volume of 645,262 shares, the short-interest ratio is presently 3.0 days. Approximately 3.5% of the shares of the stock are short sold.

Hedge Funds Weigh In On Pyxis Oncology

A number of large investors have recently bought and sold shares of the stock. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Pyxis Oncology during the second quarter valued at approximately $26,000. Kingstone Capital Partners Texas LLC purchased a new position in shares of Pyxis Oncology in the second quarter worth $37,000. XTX Topco Ltd bought a new stake in Pyxis Oncology during the 2nd quarter valued at $40,000. Velan Capital Investment Management LP bought a new stake in Pyxis Oncology during the 2nd quarter valued at $44,000. Finally, Persistent Asset Partners Ltd purchased a new stake in Pyxis Oncology during the 3rd quarter valued at $77,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on PYXS. Guggenheim boosted their price target on shares of Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Wednesday, October 8th. Wall Street Zen cut Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Royal Bank Of Canada lowered their price target on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, December 18th. Finally, Stifel Nicolaus assumed coverage on Pyxis Oncology in a report on Monday, November 3rd. They issued a “buy” rating and a $9.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $7.20.

Pyxis Oncology Stock Performance

PYXS stock opened at $1.14 on Friday. The firm has a market cap of $70.67 million, a P/E ratio of -0.71 and a beta of 1.37. The firm’s fifty day moving average is $3.83 and its 200 day moving average is $2.37. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01. As a group, analysts forecast that Pyxis Oncology will post -1.04 EPS for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.